Isotope Labelling
Secure & rapid delivery of isotopically labelled (14C/SIL) materials for non-clinical & clinical human studies.
With over 30 years of successful delivery on-site, Quotient Sciences' highly trained chemists have extensive chemical and radiochemical knowledge and the experience required to supply consultancy and advice on the most suitable labelling positions for a variety of molecular entities.
Isotope Labelling Services Include:
•GMP & non GMP synthesis
•14C radiolabelling
•Ability to handle highly potent/high hazard compounds (cytotoxics)
•Synthesis of metabolites & reference standards aiding bioanalytical and metabolism studies
•Degradants and process impurities to support API development
•Route development and precursor synthesis for labelling with 3H and short-lived isotopes 11C and 18F
•Classical and non-classical synthetic techniques
•Flow chemistry
•Automated peptide synthesis capability
•Microbiological and bio-catalysis
•Stable isotope label (SIL) synthesis, including 2H, 13C, 15N & 18O
Isotope Labelling Resources
-
Info SheetIsotope LabellingWhether you need isotopically labelled (14C/SIL) compounds for nonclinical or clinical metabolism studies and the quantification of materials in biological matrices, our expertise provides the necessary labelled materials tailored to support your studies.
-
Case StudiesStable Isotope Labelling Case StudyMultiple, biotechnology and large-pharma companies needing isotope labelling support for their ADME/hAME studies
-
WebinarMoving Drug Substance Off the Critical Path — Streamlined Strategies to Accelerate to First-in-Human & BeyondJoin Quotient’s Director of Drug Development Consulting, Dr Stephen McQuaker Vice President of Bioanalysis, Dr Stuart McDougall, as he explores case studies to demonstrate how drug substance and drug product development plans can be accelerated through innovative science and expertise to get drug substance off the critical path.
-
WebinarOvercoming Complex Formulation Challenges: Integrated Strategies for Poor Solubility, Modified Release & PediatricsJoin Quotient’s Executive Director of Drug Development Consulting, John McDermott, as he discusses how an integrated program design can simplify development processes for complex molecules and reduce overall costs.
Ready to get started?
Connect With Quotient Today